Quidel has agreed to pay $400 million plus $40 million in contingent consideration for Alere's Triage MeterPro cardiovascular and toxicology assets and Triage B-type naturietic peptide assay business. The purchase, which is subject to completion of Abbott's acquisition of Alere, would allow for geographic diversification of Quidel's business and provide a wider portfolio of rapid diagnostic products in critical care, Quidel said.
Alere's Triage assets to be acquired by Quidel in $440M deal
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.